Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of ABBV-903 Immediate Release Formulations in Healthy Volunteers
NCT05836506Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of limnetrelvir in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events up to 44 days, Maximum Plasma Concentration up to 14 days and 4 more. Started Apr 2023; status: completed.
02
Drugs
limnetrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05836506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05836506.